Table 1.
Baseline patient and first-line treatment characteristics of the entire cohort
| Characteristic | de novo DLBCL (N = 95) | tFL (N = 17) | ||||
|---|---|---|---|---|---|---|
| n | % | Missing | n | % | Missing | |
| Male | 66 | 69 | 0 | 10 | 59 | 0 |
| Age >60 y | 62 | 65 | 0 | 9 | 53 | 0 |
| Ann Arbor stage III/IV | 56 | 59 | 0 | 12 | 86 | 3 |
| ECOG performance status >1 | 41 | 43 | 0 | 7 | 50 | 3 |
| Elevated LDH | 56 | 64 | 7 | 9 | 60 | 2 |
| Extranodal sites (any) | 60 | 63 | 0 | 10 | 77 | 4 |
| Extranodal site >1 | 21 | 22 | 0 | 9 | 69 | 4 |
| IPI 0-2 | 43 | 49 | 7 | 6 | 46 | 4 |
| IPI 3 | 17 | 19 | 7 | 3 | 23 | 4 |
| IPI 4-5 | 28 | 32 | 7 | 4 | 31 | 4 |
| CHOP-containing regimen | 86 | 91 | 0 | 14 | 82 | 0 |
| Rituximab given | 90 | 95 | 0 | 11 | 65 | 0 |
| Palliation | 2 | 2 | 0 | 2 | 12 | 0 |
| Intensive regimen* | 7 | 7 | 0 | 1 | 6 | 0 |
Median age for all patients is 64 years (range 28-87). For the de novo DLBCL patients, median duration of follow-up for living patients is 7.5 years (range 1.5-16).
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase.
*
Regimens included R-CODOX-M/IVAC (rituximab with cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine), GDP (gemcitabine, dexamethasone, and cisplatin), and DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with rituximab).